解开血蛋白质组:用于差异性痴呆症诊断的开创性生物标志物
Haşim Gezegen1,2, Merve Alaylıoğlu3, Erdi Şahin2
1Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
概括
这项研究确定了化的Tau217 (pTau217) 作为诊断阿尔茨海默病和其他痴呆症的高度准确的生物标志物. 新的等离子体标志物也被发现用于非侵入性地区分痴呆症类型.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 蛋白质组学是指蛋白质组学.
背景情况:
- 诊断阿尔茨海默病 (AD) 是具有挑战性的,因为其症状与其他痴呆症重叠.
- 目前的诊断生物标志物往往具有侵入性,需要更少的侵入性替代品.
研究的目的:
- 通过使用新的NULISA蛋白质组学平台,评估已知生物标志物的诊断准确性.
- 发现用于不同类型痴呆症差异诊断的新型血生物标志物.
主要方法:
- 来自248名患有阿尔茨海默病,勒维体痴呆症 (DLB),前性痴呆症 (FTD) 和轻度认知障碍 (MCI) 的参与者的血和脑脊液 (CSF) 样本的分析.
- 使用回归模型评估等离子体生物标志物,接受器操作特征 (ROC) 曲线分析和路径丰富.
- 利用NULISA平台进行新型蛋白质组学分析.
主要成果:
- 化的Tau217 (pTau217) 在AD,DLB和FTD的诊断准确度很高 (AUC:0.9,0.84,0.79).
- 与AD相比,CXCL1,SNAP25,TREM1,β-synuclein和TEK被确定在DLB和FTD中表达不同.
- 途径分析揭示了跨痴呆类型的共享和独特的星系细胞,突触和炎症机制.
结论:
- 血pTau217已被确立为阿尔茨海默病和相关痴呆症的强大的诊断标志物.
- 确定了用于痴呆症差异诊断的新型血生物标志物.
- 非侵入性血生物标志物为痴呆症诊断和区分提供了一个有希望的方法.
关键词:
AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD ADD was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was wasDLB DLB 的意思是DLB 的意思这是一个FTD.痴呆症 痴呆症是一种痴呆症.在pTauTau pTau血生物标志物 血生物标志物
相关概念视频
01:30Dementia
173
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
173
01:26Alzheimer's Disease: Overview
675
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
675